Emergent BioSolutions and Pro Football Legend Emmitt Smith Raise Awareness of Ready to Rescue Campaign Timed to the Big Game in New Orleans
- Despite the recently reported national decline in opioid overdose deaths, many
U.S. communities, includingNew Orleans , continue to see an increase in accidental drug-related deaths year over year
- The ‘Lay, Spray, Stay’ opioid overdose educational video featuring Smith and how to use NARCAN® Nasal Spray will appear on local taxi television screens throughout the city
- Hundreds of NARCAN® Nasal Spray cartons will be given away to people in
New Orleans throughout the weekend
Recent data reported by the
That’s why Emergent’s public education campaign with Smith explaining how to administer NARCAN® Nasal Spray using three simple steps – Lay, Spray, Stay – will be displayed via taxi television screens throughout the city leading up to Sunday’s game. Smith will also be speaking to national and local media onsite to highlight how this life-saving medication can reverse the effects of an opioid poisoning in minutes and is available over the counter giving everyone the power to save a life.
“All eyes will be on
Learn more about how you can access NARCAN® Nasal Spray and be prepared to save a life at NARCAN.com.
Emmitt Smith is a paid spokesperson for Emergent.
About NARCAN® Nasal Spray
NARCAN® Naloxone HCl Nasal Spray 4 mg is the first FDA-approved, over-the-counter (OTC) 4 mg naloxone product for the emergency treatment of opioid overdose. NARCAN® Nasal Spray is not a substitute for emergency medical care. Repeat dosing may be necessary. Use as directed.
About Emergent BioSolutions
At Emergent, our mission is to protect and enhance life. For over 25 years, we’ve been at work defending people from things we hope will never happen—so we are prepared just in case they ever do. We provide solutions for complex and urgent public health threats through a portfolio of vaccines and therapeutics that we develop and manufacture for governments and consumers. We also offer a range of integrated contract development and manufacturing services for pharmaceutical and biotechnology customers. To learn more about how we plan to protect or enhance 1 billion lives by 2030, visit our website and follow us on LinkedIn, X, Instagram, Apple Podcasts and Spotify.
Safe Harbor Statement
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, are forward-looking statements. We generally identify forward-looking statements by using words like “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “forecast,” “future,” “goal,” “intend,” “may,” “plan,” “position,” “possible,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would,” and similar expressions or variations thereof, or the negative thereof, but these terms are not the exclusive means of identifying such statements. Forward-looking statements are based on our current intentions, beliefs and expectations regarding future events based on information that is currently available. We cannot guarantee that any forward-looking statements will be accurate. Readers should realize that if underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could differ materially from our expectations. Readers are, therefore, cautioned not to place undue reliance on any forward-looking statements. Any forward-looking statement speaks only as of the date of this press release, and, except as required by law, we do not undertake any obligation to update any forward-looking statement to reflect new information, events or circumstances.
There are a number of important factors that could cause the company’s actual results to differ materially from those indicated by any forward-looking statements. Readers should consider this cautionary statement, as well as the risk factors and other disclosures included in our periodic reports filed with the
Investor Contact:
Executive Vice President, CFO
lindahlr@ebsi.com
Media Contact:
Assal Hellmer
Vice President, Communications
mediarelations@ebsi.com
i
ii 2023 Coroner's Report on Accidental Drug-Related Deaths in
iii 2023 Annual Opioid Report

Source: Emergent BioSolutions